Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in Chronic Angina (ERICA)
NCT00091429Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Angina Pectoris (AP) comparing Ranolazine with Placebo (2 arms). Primary endpoint: Weekly Angina Frequency at 6 weeks. Started Aug 2004; status: completed.
02
Drugs
ranolazine
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT00091429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091429.